We claim:

1. A method to treat spinal cord damage; spinal cord trauma; neuronal tissue damage produced by an ischemic attack, infarction, hemorrhage or aneurysm; Huntington's disease; myelopathy; myelitis; or syringomyelia, comprising administering to a patient in need thereof an effective amount of an FGF-20 polypeptide or a biologically active fragment thereof.

2. The method of claim 1, wherein said FGF-20 polypeptide is human.

3. The method of claim 2, wherein said polypeptide has FGF-20 specific immunogenic activity.

4. The method of claim 1, wherein said polypeptide comprises amino acid 1 to amino acid 211 as set forth in Fig. 1.

5. The method of claim 1,wherein said polypeptide has 95% sequence identity to amino acid 1 to amino acid 211 of human FGF-20 as set forth in Fig. 1, and wherein said FGF-20 has FGF activity.

6. The method of claim 2,wherein said polypeptide has 95% sequence identity to amino acid 1 to amino acid 211 of human FGF-20 as set forth in Fig. 1, and wherein said FGF-20 has FGF activity.

7. A method to treat spinal cord damage; spinal cord trauma; neuronal tissue damage produced by an ischemic attack, infarction, hemorrhage or aneurysm; Huntington's disease; myelopathy; myelitis; or syringomyelia, comprising administering to a patient in need thereof an effective amount of a nucleic acid having a nucleotide sequence coding for an FGF-20 polypeptide or a biologically active fragment thereof.

8. The method of claim 7, wherein said nucleic acid is human.

9. The method of claim 8, wherein the nucleotide sequence codes without interruption for FGF-20.

10. The method of claim 7, wherein the nucleotide sequence has 95% sequence identity to the nucleotide sequence set forth in Fig. 1.

11. The method of claim 8, wherein the nucleotide sequence has 95% sequence identity to the nucleotide sequence set forth in Fig. 1.

12. A method to treat an adrenal leukodystrophy, progressive multifocal leukoencephalopathy, encephalomyelitis, Guillian-Barre syndrome, paraproteinemia, or chronic inflammatory demyelinating polyneuropathy, comprising administering to a patient in need thereof an effective amount of a nucleic acid having a nucleotide sequence coding for an FGF-20 polypeptide or a biologically active fragment thereof.

13. The method of claim 12, wherein said FGF-20 polypeptide is human.

14. The method of claim 13, wherein said polypeptide has FGF-20 specific immunogenic activity.

15. The method of claim 12, wherein said polypeptide comprises amino acid 1 to amino acid 211 as set forth in Fig. 1.

16. The method of claim 12, wherein said polypeptide has 95% sequence identity to amino acid 1 to amino acid 211 of human FGF-20 as set forth in Fig. 1, and wherein said FGF-20 has FGF activity.

17. The method of claim 13, wherein said polypeptide has 95% sequence identity to amino acid 1 to amino acid 211 of human FGF-20 as set forth in Fig. 1, and wherein said FGF-20 has FGF activity.

18. A method to treat an adrenal leukodystrophy, progressive multifocal leukoencephalopathy, encephalomyelitis, Guillian-Barre syndrome, paraproteinemia, or chronic inflammatory demyelinating polyneuropathy, comprising administering to a patient in need thereof an effective amount of a nucleic acid having a nucleotide sequence coding for an FGF-20 polypeptide or a biologically active fragment thereof.

19. The method of claim 18, wherein said nucleic acid is human.

20. The method of claim 19, wherein the nucleotide sequence codes without interruption for FGF-20.

21. The method of claim 18, wherein the nucleotide sequence has 95% sequence identity to the nucleotide sequence set forth in Fig. 1.

22. The method of claim 19, wherein the nucleotide sequence has 95% sequence identity to the nucleotide sequence set forth in Fig. 1.

23. A method to promote graft survival, comprising administering to a patient in need thereof an effective amount of an FGF-20 polypeptide or a biologically active fragment thereof.

24. The method of claim 23, wherein said FGF-20 polypeptide is human.

25. The method of claim 24, wherein said polypeptide has FGF-20 specific immunogenic activity.

26. The method of claim 23, wherein said polypeptide comprises amino acid 1 to amino acid 211 as set forth in Fig. 1.

27. The method of claim 23, wherein said polypeptide has 95% sequence identity to amino acid 1 to amino acid 211 of human FGF-20 as set forth in Fig. 1, and wherein said FGF-20 has FGF activity.

28. The method of claim 24, wherein said polypeptide has 95% sequence identity to amino acid 1 to amino acid 211 of human FGF-20 as set forth in Fig. 1, and wherein said FGF-20 has FGF activity.

29. A method to promote graft survival, comprising administering to a patient in need thereof an effective amount of a nucleic acid having a nucleotide sequence coding for an FGF-20 polypeptide or a biologically active fragment thereof.

30. The method of claim 29, wherein said nucleic acid is human.

31. The method of claim 30, wherein the nucleotide sequence codes without interruption for FGF-20.

32. The method of claim 29, wherein the nucleotide sequence has 95% sequence identity to the nucleotide sequence set forth in Fig. 1.

33. The method of claim 30, wherein the nucleotide sequence has 95% sequence identity to the nucleotide sequence set forth in Fig. 1.